Shares of Cohance Lifesciences experienced a remarkable 20% increase in early trading on Monday, reaching ₹432.1 per share on the National Stock Exchange (NSE), up from the previous close of ₹360.1. This surge follows the announcement of Umang Vohra as the new executive chairman and group CEO, effective from May 1, 2026, and May 20, 2026, respectively. Vohra takes over from Vivek Sharma, who is stepping down for personal reasons but will remain as an advisor for nine months to ensure a smooth transition. Investors are optimistic about Vohra's leadership, given his successful tenure as CEO of Cipla Limited, where he transformed the company into a diversified global pharmaceutical entity. Cohance Lifesciences operates a technology-driven integrated Contract Development and Manufacturing Organisation (CDMO) platform, specializing in complex chemistry and advanced API development. Vohra expressed enthusiasm for joining Cohance, highlighting the company's potential for long-term value creation. Industry experts believe that his experience will enhance Cohance's growth trajectory and strengthen its market position.